Young BC patients have also been definitively demonstrated to have a higher proportion of invasive molecular subtypes, including triple-negative and HER-2–positive subtypes; higher rates of distant disease at initial diagnosis; and poor long-term survival outcomes compared with older patients [13-15]. This evidence concerns the gene ERBB2 and breast cancer.